Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.06 and traded as high as $0.06. Mateon Therapeutics shares last traded at $0.06, with a volume of 363,734 shares.
Mateon Therapeutics Trading Up 3.4%
The stock’s 50 day moving average price is $0.04 and its 200 day moving average price is $0.06. The company has a market capitalization of $5.41 million, a price-to-earnings ratio of -3.00 and a beta of 1.33.
About Mateon Therapeutics
Mateon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies that selectively target tumor tissue. The company’s platform leverages tumor-activated peptides designed to bind to the fibrin–fibronectin complexes uniquely present in solid tumors, with the goal of improving the therapeutic index of cytotoxic payloads while limiting off-target effects.
Its lead asset, MH1, is a peptide–drug conjugate in Phase I clinical trials for advanced solid tumors.
Featured Stories
- Five stocks we like better than Mateon Therapeutics
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
